Galen takes over POA Pharma, expands reach

Irish pharma firm Galen has announced the completion of its POA Pharma (POA) acquisition. The company has stated that the multi-million pound takeover will help to “significantly expand” its global reach and product portfolio in exciting new therapy areas, such as rare metabolic disease. The deal first got underway back in April 2016, when Galen signed a distribution agreement with POA, allowing the company to market and sell POA’s metabolic product portfolio in the UK and Ireland. As a results of the acquisition, Galen hopes to extend its global footprint into the Nordic territory and Northern Europe, as POA currently represents 16 producers from 10 countries and retains a “strong portfolio of products and an extensive network worldwide.”